1. Lin, X., Wong, R. N. S., Tang, J. (1989) "Synthesis, purification, and active site mutagenesis of recombinant porcine pepsinogen". J. Biol. Chem. 264: 4482-4489.
2. Lin, X., Lin, Y., Koelsch, G., Gustchinas, A., Wlodawer, A., Tang, J. (1992) "Enzymic activities of tow-chair pepsinogen, two-chain pepsin, and the amino-terminal lobe of pepsinogen". J. Biol. Chem. 267: 17257-17263.
3. Lin, X., Loy, J. A., Sussman, F., Tang, J. (1993) "Conformational instability of the N- and C-terminal lobes of porcine pepsin in neutral and alkaline solutions". Prot. Sci. 2: 1383-1390.
4. Chen, Z., Koelsch, G., Han, H., Wang, X., Lin, X., Hartsuck, J. A., Tang, J. (1991) "Recombinant rhizopuspepsinogen Expression, Purification and activation properties of recombinant rhizopuspepsinogens". J. Biol. Chem. 266: 11718-11725.
5. Lin, Y., Fusek, M., Lin, X., Hartsuck, J. A., Kezdy, F. J., Tang, J. (1992) "pH dependence of kenetic parameters of pepsin, rhizopuspepsin, and their active-site hydrogen bond mutants". J. Biol. Chem. 267: 18413-18418.
6. Lin, X., Liu, M., Tang, J. (1992) "Heterologous expression of thermopsin, a heat-stable acid proteinase". Enzyme Microb. 14: 696-701.
7. Lin, Y., Lin, X., Hong,L., Foundling, S., Heinrikson, R. L., Thaisrivongs, S., Leelamanit, W., Raterman, D., Shaw, M., Dunn, B. M., Tang, J. (1995) "Effect of point mutations on the kinetics and inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance". Biochemistry 34: 1143-1152.
8. Ermolieff, J., Lin, X. Tang, J. (1997) "Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo". Biochem. 36: 12364-12370.
9. Lin, X., Tang, J., Koelsch, G., Monod, M., Foundling, S. (1993) "Recombinant canditropsin, and extracellular aspartic protease from yeast candida tropicalis". J. Biol. Chem. 268: 20143-20147.
10. Koelsch, G., Tang, J., Monod, M., Foundling, S. I., Lin, X. 1998. in Aspartic Proteinases, "Primary substrate specificities of secreted aspartic proteases of candida albicans" James (Plenum Press, New York), pp. 335-338.
11. Wang, C. S., Dashti, A. & Downs, D. (1999) " Bile salt-activated lipase Publication Types: Review , Review, tutorial". Methods Mol. Biol. 109: 71-79.
12. Wang, C. S., Downs, D., Dashti, A. & Jackson, K. W. (1996) "Isolation and characterization of recombinant human apolipoprotein C-II expressed in Escherichia coli". Biochim Biophys Acta 1302: 224-30.
13. Wang, X., Lin, X., Loy, J. A., Tang, J., Zhang, X. C. (1998) "Crystal structure of the catalytic domain of human plasmin complexed with streptokinase". Science 281: 1662-1665.
14. Wang, X., Terzyan, S., Tang, J., Loy, J. A., Lin, X. & Zhang, X. C. (2000) "Human plasminogen catalytic domain undergoes an unusual conformational change upon activation". J Mol Biol 295: 903-14.
15. Faro, C., Ramal-Santos, M., Vieira, M., Mendes, A., Simoes, I., Andrade, R., Verissimo, P., Lin, X., Tang, J. & Peres, E. (1999) "Cloning and characterization of cDNA encoding cardosin A, and RGD containing plant aspartic proteinase". J. Biol. Chem. 274: 28724-28729.
16. Lin, X., Koelsch, G., Wu, S., Downs, D., Dashti, A. & Tang, J. (2000) "Human aspartic protease memapsin 2 cleaves the b-secretase site of b-amyloid precursor protein". Proc. Natl. Acad. Sci. USA 97: 1456-1460.
17. Ghosh, A. K., Shin, D., Downs, D., Koelsch, G., Lin, X., Ermolieff, J. & Tang, J. (2000) "Design of potent inhibitors for human brain memapsin 2 (beta-secretase)". J. Am. Chem. Soc. 122: 3522-3523.
18. Hong, L., Koelsch, G., Lin, L., Wu, S., Terzyan, S., Ghosh, A., Zhang, X. & Tang, J. (2000) "Structure of Memapsin 2 (beta-secretase) complexed with inhibitor: a template to design drugs for Alzheimer's Disease". Science 290: 150-153.
19. Koelsch, G., Tang, J., Loy, J. A., Monod, M., Jackson, K., Foundling, S. I. & Lin, X. (2000) "Enzymic characteristics of secreted aspartic proteases of Candida albicans". Biochim Biophys Acta 1480: 117-131.
20. Chew LJ, Pan H, Yu J, Tian S, Huang WQ, Zhang JY, Pang S, Li LY. A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J. 2002 Mar 26.
21. Yu J, Tian S, Metheny-Barlow L, Chew LJ, Hayes AJ, Pan H, Yu GL, Li LY. Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor. Circ Res. 2001 Dec 7;89(12):1161-7.
22. Zhai Y, Yu J, Iruela-Arispe L, Huang WQ, Wang Z, Hayes AJ, Lu J, Jiang G, Rojas L, Lippman ME, Ni J, Yu GL, Li LY. Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer. 1999 Jul 2;82(1):131-6.
23. Zhai Y, Ni J, Jiang GW, Lu J, Xing L, Lincoln C, Carter KC, Janat F, Kozak D, Xu S, Rojas L, Aggarwal BB, Ruben S, Li LY, Gentz R, Yu GL. VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J. 1999 Jan;13(1):181-9.
24. Yong-Tae Kim, Deborah Downs, Shili Wu, Azar Dashti, Yujun Pan, Peng Zhai, Xinjuan Wang, Xuejun C. Zhang and Xinli Lin. (2002) “Enzymic Properties of Recombinant BACE2”. Eur. J. Biochem. 269:1-11.

Operating Principle